Also, because the chemoresistance effect of Sox2 is mediated by hyperactivation of the PI3K/Akt signaling, it appears that targeted therapy against Sox2 administered in combination with paclitaxel may be a promising therapy in chemoresistant prostate cancer (Li et al., 2014). The gene discussed is SOX2; the disease is prostate cancer.